Clinical trials of the vaccine are currently underway. & LaquoSputnik V »is a two-component vaccine. Revaccination is carried out at intervals of 3-4 weeks. Moreover, by reintroduction, the coronavirus RNA particle is covered with new adenovirus. This is done to rule out the presence of neutralizing antibodies against the vaccine in humans and thus increase the reliability of repeated injections. The vaccine article & laquoSputnik V »was published by the international peer-reviewed scientific journal Lancet.
“Since the beginning of the pandemic, BIOCAD has repeatedly stated that the company is ready to become an industrial partner for any project aimed at developing a coronavirus vaccine,” commented Dmitry Morozov, CEO of biotechnology company BIOCAD. : “We carefully studied the results of our colleagues and concluded that a study of the vaccine, conducted by a team of a scientific institute led by Alexander Gintsburg, showed that this is a reliable product, effective enough and safe to ensure vaccination of Russian citizens. the third phase of clinical trials, including many volunteers, and begin delivery of vaccines to regions of Russia, as well as abroad. ”
In addition to the production of the liquid vaccine, the partners plan to organize the production of a lyophilized (powder form) version of the vaccine. The dry vaccine does not require special storage conditions during transport, which is a major advantage.
At the beginning of September 2020, the biotechnology company BIOCAD launched a new high-tech production complex in Zelenograd, with a total area of 43 thousand square meters. Thus, the company has 9 newest production facilities in Russia, four of which are located in Moscow and the Moscow region. In total, the company employs over 2.5 thousand people, of which 1000 are involved in its research activities. This is the fourth vaccine development project in which BIOCAD is involved. BIOCAD independently leads two vaccine developments, and in another project of the Vector Science Center, the company also acts as an industrial partner.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of the announcements published on EurekAlert! by contributing to institutions or using any information through the EurekAlert system.